Roche To Stop Selling Early HIV Drug HIVID
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will continue to supply zalcitabine, one of the first nucleoside reverse transcriptase inhibitors, through the end of the year.
You may also be interested in...
Shire/Avexa Expand Agreement On HIV Candidate Apricitabine
Acquisition of North American marketing rights to the novel nucleoside reverse transcriptase inhibitor gives Australian biotech Avexa worldwide commercialization rights.
Shire/Avexa Expand Agreement On HIV Candidate Apricitabine
Acquisition of North American marketing rights to the novel nucleoside reverse transcriptase inhibitor gives Australian biotech Avexa worldwide commercialization rights.
Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy
The Bristol/Gilead combination product will launch within seven business days.